Opioid Marketing Fraud: Prescriber Payments, Coverage Scripts and Drug Distribution

Opioid marketing fraud uses prescribing inducements or misleading sales and reimbursement claims to generate opioid revenue at patients’ and taxpayers’ expense. A payment can influence the prescription, a false coverage submission can get it paid, and a pharmacy arrangement can keep it moving after another pharmacist refuses it. If you work inside that sequence, you may know which decision the company paid to change.

The manufacturer’s sales team, the reimbursement staff and the dispensing pharmacy see different parts of the same business. The civil cases against Purdue and Insys show why those parts belong together. They connect the effort to sell an opioid with the representations and payments that helped turn it into a reimbursed prescription.

Purdue’s Payments Reached Prescribers and Their Software

Purdue sold OxyContin and allegedly paid prescribers and an electronic health record company to influence opioid prescribing. The Justice Department’s October 2020 announcement described a nationwide speaker-program allegation and a civil agreement establishing a $2.8 billion claim in Purdue’s bankruptcy. A speaker fee puts money in the prescriber’s hands. A payment to a software company can put the manufacturer’s influence inside the system the prescriber uses.

The software-payment allegation reaches beyond the sales representative’s visit. It puts the commercial relationship inside a tool used in patient care. What did the manufacturer pay to have the prescriber see?

The government’s civil allegations also described a sales effort aimed at extreme, high-volume prescribers. Under a program called Evolve to Excellence, sales representatives allegedly intensified their OxyContin marketing to prescribers already writing 25 times as many OxyContin prescriptions as their peers.

Purdue allegedly learned that a doctor was prescribing extraordinarily high doses, yet sent sales representatives to meet with that doctor more than 300 times. The alleged response to dangerous prescribing was more sales visits.

How Do Pharmaceutical Kickbacks Work?

Pharmaceutical kickbacks buy a prescribing or purchasing decision through a payment or benefit. In the Insys civil case, the government alleged that speaker payments helped generate medically unnecessary prescriptions for Subsys, its fentanyl spray, and that false reimbursement submissions helped get those prescriptions paid.

Insys agreed to a $195 million civil False Claims Act settlement in June 2019. The civil allegations came from five qui tam cases brought by whistleblowers that the government joined.

A whistleblower’s complaint quotes an Insys executive’s text:

The demand in that text is for daily prescriptions. It gives an insider something concrete to recognize beside the speaker-program label: what management expected the relationship to produce.

The payment record and the prescription record answer different questions. One shows who received the money. The other shows the business the relationship generated. An employee who knows how speakers were chosen or how their prescribing was discussed may understand the connection that neither record explains alone.

Prior Authorization Carries the Sale to the Payer

Prior authorization is one way a health plan controls access to a drug. False reimbursement submissions were a separate part of the Insys civil allegations. Buying the prescribing decision and obtaining payment for the prescription are different steps. The person speaking to the payer may know what was said about a patient even if that person never attended a speaker event.

In a coverage inquiry, we compare the information supporting the prescription with the account presented for payment. A call script, a submitted prior authorization request and the patient’s diagnosis can reveal where those accounts diverge. The question is whose information reached the payer and who decided what that information would say.

When Another Pharmacy Had Already Refused

Purdue allegedly contracted with certain specialty pharmacies to fill opioid prescriptions that other pharmacies had rejected as potentially lacking medical necessity. The government’s civil allegation puts the commercial arrangement at a very specific point: after a pharmacist had already questioned the prescription.

The manufacturer could gain a sale by finding a pharmacy willing to fill it. In that alleged arrangement, the contract helped overcome the earlier refusal. The pharmacy’s role therefore belongs beside the prescriber’s role and the coverage submission when examining how the prescription moved through the business.

Opioid Distribution Turns on Orders and Dispensing

Opioid distribution cases concern the movement of drugs and the response to suspicious orders or prescriptions. Wholesalers handle inventory, credit, controlled-substance compliance, specialty distribution and delivery. Those functions give distribution employees a different view of the business from the manufacturer representative calling on a doctor.

The government’s complaint alleged that Rite Aid disregarded pharmacists’ concerns, dispensing reports showing problematic prescribing and distributor warnings about unusually large oxycodone orders at particular stores.

The complaint also alleged that Rite Aid directed employees to delete pharmacists’ internal notes about suspicious prescribers from its dispensing software. The alleged failure reached the warning itself. Removing it kept information another pharmacist could have used out of the system.

In its July 2024 civil settlement announcement, the Justice Department said the resolution addressed unlawful dispensing and associated false claims. Former Rite Aid pharmacy employees had brought whistleblower claims. Their position inside the pharmacies gave this case a different starting point from a manufacturer’s sales program.

Indivior and the Product’s Safety Story

Opioid marketing allegations can also concern the safety claims used to sell a product. Indivior’s Suboxone civil case addressed alleged safety and marketing representations that caused false claims. Its July 2020 resolution included a $300 million civil settlement resolving claims in six whistleblower lawsuits.

That mechanism directs attention to the message itself. What did the company say about the drug, what information supported that statement and how did the statement affect the claim for payment?

What Evidence Is Needed to Prove Fraud?

The evidence needs to connect the company’s payment or statement to the prescription and the claim for reimbursement. Our whistleblower experts work with you to establish how decisions spread across sales, coverage and dispensing fit together.

Public Citizen’s 2018 report, Twenty-Seven Years of Pharmaceutical Industry Criminal and Civil Penalties: 1991 Through 2017, found that all but one of the five single-state settlements in 2016 and 2017 involved Insys or Endo and alleged unlawful promotion or kickbacks involving their opioid drugs.

The False Claims Act reaches a manufacturer that knowingly causes false government claims, including Medicare claims submitted by a pharmacy or physician. The connection between the company’s conduct and the healthcare payment is where we focus with you. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What the Company Wanted

If you know which prescribers the company paid, what its reimbursement staff said or why a pharmacy kept filling rejected prescriptions, speak with our whistleblower experts about the opioid business you saw from inside. We build the connection between that knowledge and the government payments, bring in pharmaceutical whistleblower lawyers who understand opioid marketing and reimbursement cases, and stand beside you throughout the case.